A new breakthrough from the University of Saskatchewan could potentially shorten the demanding calving season for beef producers. The innovation involves using Cetrorelix, a hormone drug typically used in human IVF treatments, which has shown promising results for use in cattle. Dr. Jaswant Singh, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the drug’s effectiveness in synchronizing ovulation in cows, leading to a more efficient and cost-effective breeding process.
By inducing cows to become pregnant simultaneously through IVF, Cetrorelix aims to align calving times, potentially reducing the labor-intensive period from two months to just one month. This synchronization method could not only streamline operations but also result in higher weaning weights for calves, ultimately boosting farmers’ profits.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed keen interest in integrating Cetrorelix into their breeding practices. The drug’s potential to enhance genetic selection and provide more accurate calf projections makes it an appealing option for ranchers looking to optimize their operations.
With a patent application in progress and collaborations with pharmaceutical companies underway, the university aims to bring Cetrorelix to the market soon. Dr. Singh is optimistic about the global impact of the drug, foreseeing increased adoption of artificial insemination practices in the agricultural industry. As regulatory milestones are being met, the focus now shifts to implementing this innovative solution to benefit livestock producers worldwide.